Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7980651rdf:typepubmed:Citationlld:pubmed
pubmed-article:7980651lifeskim:mentionsumls-concept:C0001675lld:lifeskim
pubmed-article:7980651lifeskim:mentionsumls-concept:C0010453lld:lifeskim
pubmed-article:7980651lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:7980651lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:7980651lifeskim:mentionsumls-concept:C0227525lld:lifeskim
pubmed-article:7980651lifeskim:mentionsumls-concept:C0065749lld:lifeskim
pubmed-article:7980651lifeskim:mentionsumls-concept:C0010762lld:lifeskim
pubmed-article:7980651lifeskim:mentionsumls-concept:C0011777lld:lifeskim
pubmed-article:7980651lifeskim:mentionsumls-concept:C1515670lld:lifeskim
pubmed-article:7980651lifeskim:mentionsumls-concept:C0851285lld:lifeskim
pubmed-article:7980651lifeskim:mentionsumls-concept:C1314677lld:lifeskim
pubmed-article:7980651lifeskim:mentionsumls-concept:C0205184lld:lifeskim
pubmed-article:7980651lifeskim:mentionsumls-concept:C0205225lld:lifeskim
pubmed-article:7980651pubmed:issue9lld:pubmed
pubmed-article:7980651pubmed:dateCreated1994-12-13lld:pubmed
pubmed-article:7980651pubmed:abstractTextWe have demonstrated recently that although rat hepatocytes rapidly lose their cytochrome P450 mRNA content following their introduction into primary culture, hepatocytes cultured on Matrigel, a reconstituted basement membrane, subsequently spontaneously "reexpress" the mRNAs of some constitutive P450 forms (Kocarek et al., Mol Pharmacol 43: 328-334, 1993). In the present study, we used the Matrigel cell culture system to examine the dose-dependent effects of dexamethasone (DEX) treatments on the mRNAs for two of the P450 forms that are reexpressed spontaneously between days 3 and 5 in culture, 2B1/2 and 2C6. Treatment of cultured hepatocytes with low doses of DEX (10(-9) to 10(-8) M) that induced the mRNA for tyrosine aminotransferase, a model glucocorticoid-inducible gene, suppressed the spontaneous appearance of 2B1/2 mRNA while having little or no effect on the level of 2C6 mRNA or on beta-actin mRNA. However, treatment of the hepatocyte cultures with high doses of DEX (10(-6) to 10(-5) M) that induced P450 3A1 mRNA increased the amounts of the 2B1/2 and 2C6 mRNAs (4.1- and 2.4-fold, respectively, at 10(-5) M DEX). In contrast to the suppressive effects on the spontaneous increases in 2B1/2 mRNA, low doses of DEX (10(-8) to 10(-7) M) enhanced the induction of 2B1/2 mRNA by phenobarbital (2.5-fold at 10(-7) M DEX). Treatment of the hepatocyte cultures with triamcinolone acetonide, another potent glucocorticoid, suppressed spontaneous 2B1/2 mRNA expression at low doses, but did not induce 2B1/2 mRNA at high doses. Treatments with steroids of other classes, including dihydrotestosterone, 17 alpha-ethinylestradiol, fludrocortisone or R-5020, failed to suppress 2B1/2 mRNA levels at low doses. Additionally, treatment with RU-486, a glucocorticoid/progestin receptor antagonist, induced 2B1/2 mRNA at high doses (10(-6) to 10(-5) M). The suppressive effects of DEX on spontaneous 2B1/2 mRNA expression observed at low doses are consistent with a classical glucocorticoid-mediated mechanism, while the high-dose inductive effects of DEX appear to be exerted through a nonclassical mechanism, perhaps akin to that for induction of 3A1.lld:pubmed
pubmed-article:7980651pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7980651pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7980651pubmed:languageenglld:pubmed
pubmed-article:7980651pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7980651pubmed:citationSubsetIMlld:pubmed
pubmed-article:7980651pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7980651pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7980651pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7980651pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7980651pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7980651pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7980651pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7980651pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7980651pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7980651pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7980651pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7980651pubmed:statusMEDLINElld:pubmed
pubmed-article:7980651pubmed:monthNovlld:pubmed
pubmed-article:7980651pubmed:issn0006-2952lld:pubmed
pubmed-article:7980651pubmed:authorpubmed-author:GuzelianP SPSlld:pubmed
pubmed-article:7980651pubmed:authorpubmed-author:SchuetzE GEGlld:pubmed
pubmed-article:7980651pubmed:authorpubmed-author:KocarekT ATAlld:pubmed
pubmed-article:7980651pubmed:issnTypePrintlld:pubmed
pubmed-article:7980651pubmed:day1lld:pubmed
pubmed-article:7980651pubmed:volume48lld:pubmed
pubmed-article:7980651pubmed:ownerNLMlld:pubmed
pubmed-article:7980651pubmed:authorsCompleteYlld:pubmed
pubmed-article:7980651pubmed:pagination1815-22lld:pubmed
pubmed-article:7980651pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:7980651pubmed:meshHeadingpubmed-meshheading:7980651-...lld:pubmed
pubmed-article:7980651pubmed:meshHeadingpubmed-meshheading:7980651-...lld:pubmed
pubmed-article:7980651pubmed:meshHeadingpubmed-meshheading:7980651-...lld:pubmed
pubmed-article:7980651pubmed:meshHeadingpubmed-meshheading:7980651-...lld:pubmed
pubmed-article:7980651pubmed:meshHeadingpubmed-meshheading:7980651-...lld:pubmed
pubmed-article:7980651pubmed:meshHeadingpubmed-meshheading:7980651-...lld:pubmed
pubmed-article:7980651pubmed:meshHeadingpubmed-meshheading:7980651-...lld:pubmed
pubmed-article:7980651pubmed:meshHeadingpubmed-meshheading:7980651-...lld:pubmed
pubmed-article:7980651pubmed:meshHeadingpubmed-meshheading:7980651-...lld:pubmed
pubmed-article:7980651pubmed:meshHeadingpubmed-meshheading:7980651-...lld:pubmed
pubmed-article:7980651pubmed:meshHeadingpubmed-meshheading:7980651-...lld:pubmed
pubmed-article:7980651pubmed:meshHeadingpubmed-meshheading:7980651-...lld:pubmed
pubmed-article:7980651pubmed:meshHeadingpubmed-meshheading:7980651-...lld:pubmed
pubmed-article:7980651pubmed:meshHeadingpubmed-meshheading:7980651-...lld:pubmed
pubmed-article:7980651pubmed:meshHeadingpubmed-meshheading:7980651-...lld:pubmed
pubmed-article:7980651pubmed:meshHeadingpubmed-meshheading:7980651-...lld:pubmed
pubmed-article:7980651pubmed:meshHeadingpubmed-meshheading:7980651-...lld:pubmed
pubmed-article:7980651pubmed:year1994lld:pubmed
pubmed-article:7980651pubmed:articleTitleBiphasic regulation of cytochrome P450 2B1/2 mRNA expression by dexamethasone in primary cultures of adult rat hepatocytes maintained on matrigel.lld:pubmed
pubmed-article:7980651pubmed:affiliationDepartment of Medicine, Medical College of Virginia, Richmond.lld:pubmed
pubmed-article:7980651pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7980651pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:7980651pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:7980651pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7980651lld:pubmed